PharmaBoardroom

Aziz Mrabti – Director General, Medicines & Pharmacy…

General Director Dr Aziz Mrabti discusses the Moroccan Medicines & Pharmacy Directorate (DMP)’s transition to an independent…

Camilia Benani – Partner, DLA Piper Morocco

Camilia Benani, recently promoted to partner at DLA Piper's Casablanca office, explains why the Moroccan healthcare sector has become a lightning rod…

Hong Kong: Towards a Fully-Fledged Regulator of its Own?

Hong Kong provides some of the best and most efficient healthcare in Asia, with Hong Kongers living to over 85 on average (compared to 83 in Singapore…

Sara Al Dallal – President, Emirates Health Economics…

Founded in July 2020, the Emirates Health Economics Society - led by Dr Sara Al Dallal - aims to create a space for the discussion of health economics…

New EFPIA Board Tackles EU Pharma Legislation Reform

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has elected a new president and vice presidents who have set out a key…

The African Medicines Agency and the Evolution of Continental…

Writing in the July 2023 edition of DIA’s Global Forum magazine, Nevena Miletic of Roche and the IFPMA’s Africa Regulatory Network and Ian Hudson…

Can the UK’s New Life Sciences Plan Save Its Global…

Life sciences have been steadily losing ground in the UK with a significant drop in global R&D investments and a decreasing number of patients…

Four Industry Leaders on Middle East Regulatory & Access…

With a welter of regulatory upgrades in the UAE and Saudi Arabia in recent years, patients in the Middle East’s leading countries now have wider and…

Saudi FDA Becomes First Arab Member of PIC/S Pharma Inspection…

The Saudi Food and Drug Authority (SFDA) has joined the Pharmaceutical Inspection Co-operation Scheme (PIC/S), aimed at harmonising inspection…

Regulatory Reliance: Practical Solutions for Patients

Writing in the June 2023 edition of DIA’s Global Forum magazine, Angelika Joos of MSD and Susanne Ausborn Roche consider some of the key takeaways…

BIO2023: FDA CBER’s Peter Marks on COVID-19 Regulatory Impact

During a panel discussion at the BIO International Convention, Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research…

4 Key Priorities for the European Medicines Agency in 2023

As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer…

Tagged with Regulator